Irina Apostolou
Corporate Officer/Principal en CONSTELLATION PHARMACEUTICALS, INC. .
Cargos activos de Irina Apostolou
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2016 | - |
Office of Technology Development
 Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Corporate Officer/Principal | - | - |
Historial de carrera de Irina Apostolou
Antiguos cargos conocidos de Irina Apostolou.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01/10/2011 | 31/07/2016 |
Formación de Irina Apostolou.
| Institut Universitaire de Technologie de Cachan | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
| Francia | 2 |
Operativa
| Corporate Officer/Principal | 3 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Finance | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Office of Technology Development
Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Irina Apostolou
- Experiencia
